Common Stock, $0.0001 par value per share
- Symbol
- NKTR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01 · 8-K
Nektar Therapeutics
NKTRNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. In August 2023, Nektar Therapeutics (the “Company”) filed a complaint in the U.S. District Court for the Northern District of California (the “District Court”) against Eli Lilly and Company (“Lilly”) alleging, among other claims, breach of contract and breach of the implied covenant of good faith and fair dealing in connection with the license agreement governing the partie…
Company context
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory Tcell stimulator being evaluated in atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus. Nektar’s pipeline also includes preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.
Current securities
Registered securities in this filing
Nektar Therapeutics · 8-K · Filed 2026-09-25
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item
8.01 Other Events.
In August 2023, Nektar
Therapeutics (the “Company”) filed a complaint in the U.S. District Court for the Northern District of California (the “District
Court”) against Eli Lilly and Company (“Lilly”) alleging, among other claims, breach of contract and breach of the implied
covenant of good faith and fair dealing in connection with the license agreement governing the parties’ prior collaboration for
the development and commercialization of rezpegaldesleukin (the “License Agreement”). The case, Nektar Therapeutics v.
Eli Lilly & Co., Case No. 3:23-cv-03943-JD, proceeded to a jury trial beginning on September 8, 2026. On September 24, 2026, the
jury returned a verdict finding that Lilly breached the implied covenant of good faith and fair dealing in the License Agreement. The
jury awarded the Company $90 million in damages plus interest to be determined by the District Court. The jury’s verdict remains
subject to post-trial proceedings, and any resulting judgment may be subject to appeal.